Buradasınız

Anasayfa » Content

High sensitive C- reactive protein and ceruloplasmin in hypertension

Journal Name:

  • Indian Journal of Basic & Applied Medical Research

Publication Year:

  • 2015

Key Words:

Author Name
Abstract (2. Language): 
Background: Essential hypertension is the most prevalent form of hypertension accounting for 90% of all cases of hypertension (HTN). HTN is prevalent all over the world. Usually it is readily detectable, easily treatable condition and it left untreated may leads to serious complications. It ranked third in the world by prevalence.HTN double the risk of cardiovascular diseases (CVD), including coronary heart disease(CHD), congestive heart failure (CHD), ischemic and hemorrhagic stroke, renal failure and peripheral arterial disease. The present study was planned to measure the serum levels of high sensitivity C-reactive protein (hs-CRP) and ceruloplasmin (Cp) in patients with essential hypertension (EHT) and to compare with controls. Material and methods: In this study total 90 subjects were included above 40-65 years of age.These patients were newly diagnosed by clinicians and blood sample were collected before starting antihypertensive treatment and 30 subjects were recruited as controls. hs-CRP and ceruloplasmin levels were measured by the methods of latex turbidometric method and turbidometric immune assay method respectively. Data were analyzed using ‘F’ test for their level of significance. Results: The mean hs-CRP and ceruloplasmin level were significantly higher in patients as compared to the control subjects. The significant correlation was observed between the levels of hs-CRP & Cp in essential hypertensive patients. Conclusions: Elevated serum hs-CRP and ceruloplasmin level might contribute to the increased susceptibility for the development of CVD in essential hypertensive patients.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-high-sensitive-c-reactive-protein-and-ceruloplasmin-hypertension.pdf
  • 2
305
309
  • English

REFERENCES

References: 

1]Chobanain AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al National Heart, Lung & Blood
pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh report of the joint
National Committee on Prevention, Detection, Evaluation & Treatment of High Blood Pressure. The JNC 7
report.JAMA;2003;289:2560-72.
2]World Health Report 2002, Reducing Risk & Promoting Healthy Life Geneva, Switzerland: World Health
Organizaation;2002:58.http://www.who.int/whr/2002.
3]Summt Gupta, Bimal K. Agrawal, Probodh K. Sehajpal & Rajesh K. Goal,Prevalence & Predictors of Essential
Hypertension in the Rural Population of Haryana, India: An Hospital Based Study.J Rural & Tropical Public
health;2011;10:29-34.
4]R. Gupta. Trends in HTN epidemiology in India. J of human HTN;2004;18:73-74.
5]Morris J. Brown. Matching the right drug to the right patient in essential hypertension, Heart 2001;86:113-120.
6]G. S. Sainani, V. G. Maru; Endothelial Cell Dysfunction in HTN. The association of Physicians of India; Med.
Update, Editor-S. K. Bichile, 2008;18:32-39.
7]Christoper J. Boos & Gregory Y. H. Lip; Is HTN an Inflammation Process? Current pharmaceutical design,
2006;12:1623-1635.
8]Joint National Committee on Prevention, Detection & Treatment of High Blood Pressure. The sixth report of the Joint
National Committee on Prevention, Detection, Evaluation & Treatment of High Blood Pressure (JNCVI) Arch. Intern.
Med. 1997;157:2413-2446.
9]Macy E. M. et al. “Clinic Chemistry”;1997;43:52-58.
10]Poulik M.D. & Kleiss M. L. et al in F. W. Putman editor, The plasma proteins. 2nd edition; Acedemic press, New
York;52-108.
308
Indian Journal of Basic and Applied Medical Research; March 2015: Vol.-4, Issue- 2, P. 305-309
306
www.ijbamr.com P ISSN: 2250-284X , E ISSN : 2250-2858
11]Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing
HTN. JAMA; 2003;290:2945-2951.
12]Pearson TA, Mensah GA, Alexander RE. et al Markers of inflammation & cardiovascular disease: application to
clinical and public health practice : a statement for health care professionals from the Centers for diseases control &
Prevention & the American Heart Association. Circulation.2003;107:499-511.
13]Abramson JL, Lewis C, Murrah NV, Anderson GT. Vaccarino V. Relation of CRP & TNF-α to ambulatory blood
pressure variability in healthy adults. Am J Cardiol, 2006;1;98 (5):649-652.
14]Kedziora K. K. Bartosz G. Pawluk H. Kornatowski T, et al Production of nitric oxide, Lipid peroxidation and
oxidase activity of ceruloplasmin in blood of elderly patients with primary hypertension. Effects of perindopril
treatment? Aging clinical exp. Res 2006;Feb 18(1):1-6.
15]HB Sirajewala, AS Dabhi, NR Malukar, RB Bhalagami, TP Pandya, Serum ceruloplasmin levels as an antioxidant in
acute myocardial infarction.JIACM,2007;8(2):135-138.

Thank you for copying data from http://www.arastirmax.com